ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia
Non-refundable funds from the Next Generation-EU programMADRID, Spain and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....